Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding

Qiao, Weiguang; Ren, Yun; Bai, Yang; Liu, Side; Zhang, Qiang; Zhi, Fachao

doi:10.1097/md.0000000000001725

Cited by 54 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, hemostatic powder application had been studied on a small scale for such difficult bleeding situations as postbanding ligation ulcer 42 ; however, to date the only validated option in this situation is a high dose of proton pump inhibitors and injection of cyanoacrylate underneath the ulcer. 43…”

Section: Hemostatic Powdermentioning

confidence: 99%

New Developments in Managing Variceal Bleeding

Ibrahim

Devière

2018

Gastroenterology

View full text Add to dashboard Cite

Section: Hemostatic Powdermentioning

confidence: 99%

New Developments in Managing Variceal Bleeding

Ibrahim

Devière

2018

Gastroenterology

View full text Add to dashboard Cite

“…This material was used safely and effectively in various medical indications for obstructing digestive, urinary and pulmonary fistulas . Besides, it was used to ensure wounds, lacerations and corneal ulcer healing, mesh fixation for inguinal hernia and adhesion of bone or cartilage as well as to control bleeding from esophageal varices . CA converts into an inert polymer on coming in contact with moisture, solidifies within 5–10 s and fixes in a minute .…”

Section: Discussionmentioning

confidence: 99%

Hysteroscopic tubal occlusion using iso‐amyl‐2‐cyanoacrylate in patients with hydrosalpinx

Amer

Ahmed

Hassan³

2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…In particular, the rebleeding rate following EVO was significantly lower than that following EVL in patients with IGV1s (OR, 0.06; 95% CI, 0.01-0.58). 183 TIPS placement and EVO are both effective treatments to control bleeding, with a hemostasis rate of more than 90%. Because of complications such as HE, stent occlusion, and higher cost, TIPS placement over EVO is not recommended as a first-line treatment.…”

Section: Treatment Of Gov2 or Igv1 Bleedingmentioning

confidence: 99%

“…bleeding rate than EVL in patients bleeding from GOV1s (OR, 0.39; 95% CI, 0.16-0.94). 155,158,183 However, those studies included only a small number of patients. In a retrospective Korean study, EVO showed beneficial outcomes, with lower 1-year rebleeding rate (3.6% vs. 30.8%, P=0.004) and bleeding-related mortality rate (5% vs. 22%, P=0.05) than EVL.…”

Section: Prevention Of Rebleedingmentioning

confidence: 99%

KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

2020

Clin Mol Hepatol

View full text Add to dashboard Cite

clinical practice. Therefore, these revised guidelines for the treatment of varices and HE are offered for Korean practice to reflect the latest research results and extensive discussions within the revision committee. This guideline contains the opinions of experts and is intended to be a practical reference for the care of patients with varices and HE; it is not an absolute standard of care. The best choices for each patient's care vary from case to case, and the judgment of the doctor in charge is important. As medical evidence and new findings accumulate in the future, these guidelines will require ongoing supplementation and revision. This guideline may not be modified or altered without permission. Target population This guideline discusses patients with varices, HE, and related complications (esophageal varices [EVs] and bleeding, gastric varices and bleeding, portal hypertensive gastropathy, covert and overt HE) caused by liver cirrhosis. It is intended for clinicians and other medical personnel who are in charge of diagnosing and treating patients with liver cirrhosis. This guideline is also intended to provide practical clinical and educational information and directions for resident physicians and fellows in training, practitioners, and their trainers and supervisors. Development, funding, and revision process Comprising 14 hepatologists, the Clinical Practice Guideline Committee for Liver Cirrhosis: Varices, HE, and related complications (the Committee) was organized by the KASL Board of Executives. Funding for the revisions was provided by KASL. Each committee member collected and analyzed source data in his or her own field, and the members then wrote the manuscript together. Literature review The Committee selected keywords and questions using PICO (Patient/Problem, Intervention, Comparison, Outcome) assessments and systematically collected and reviewed international and domestic literature available in PubMed, MEDLINE, Kore-aMed, the Korean Medical Database, and other databases. In addition to published articles, abstracts of important meetings published before January 2019 were evaluated.

show abstract

Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding

Abstract: Supplemental Digital Content is available in the text

Cited by 54 publications

References 26 publications

New Developments in Managing Variceal Bleeding

New Developments in Managing Variceal Bleeding

Hysteroscopic tubal occlusion using iso‐amyl‐2‐cyanoacrylate in patients with hydrosalpinx

KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

Contact Info

Product

Resources

About